AREG and cancer: Consistent with previous experiments using HCT116 Rab11a‐exosome preparations and HCT116 target cells (Fan et al., 2020) and with other cancer sEVs (Raimondo et al., 2019), this effect was blocked by a neutralising anti‐AREG antibody (Figure 2d), which suppressed the sEV‐induced activation via phosphorylation of the downstream signalling target ERK (Figure 2e,g).